Evidence map›Paper›PMID 32057178›Full record

ArticleJournal of cellular and molecular medicine2020

LncRNA TUG1 alleviates cardiac hypertrophy by targeting miR-34a/DKK1/Wnt-β-catenin signalling.

Qingxia Fang, Ting Liu, Chenhuan Yu, Xiuli Yang, Yanfei Shao, Jiana Shi, Xiaolan Ye, Xiaochun Zheng, Jieping Yan, Danfeng Xu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Emerging Roles of Long Non-Coding RNAs in Cardiovascular Diseases.Journal of cellular and molecular medicine · 2025
    Review
  6. Article
  7. Article
  8. Posttranscriptional Regulation by Proteins and Noncoding RNAs.Advances in experimental medicine and biology · 2024
    Article
  9. Neutrophil-like cell membrane-coated siRNA of lncRNAMolecular therapy. Nucleic acids · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. TUG1 as a Therapy Target in Pancreatic Cancer.Digestive diseases and sciences · 2020
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Qingxia FangDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Ting LiuDepartment of pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chenhuan YuKey Laboratory of Experimental Animal and Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou, China.
Xiuli YangDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Yanfei ShaoDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Jiana ShiDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xiaolan YeDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xiaochun ZhengDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Jieping YanDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Danfeng XuDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xiaozhou ZouDepartment of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou, China.ORCID 0000-0003-4355-8162
Zhejiang Provincial People's Hospital · CNHangzhou First People's Hospital · CNZhejiang Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study was designed to explore the role and underlying mechanism of lncRNA taurine up-regulated gene 1 (TUG1) in cardiac hypertrophy. Mice were treated by transverse aortic constriction (TAC) surgery to induce cardiac hypertrophy, and cardiomyocytes were treated by phenylephrine (PE) to induce hypertrophic phenotype. Haematoxylin-eosin (HE), wheat germ agglutinin (WGA) and immunofluorescence (IF) were used to examine morphological alterations. Real-time PCR, Western blots and IF staining were used to detect the expression of RNAs and proteins. Luciferase assay and RNA pull-down assay were used to verify the interaction. It is revealed that TUG1 was up-regulated in the hearts of mice treated by TAC surgery and in PE-induced cardiomyocytes. Functionally, overexpression of TUG1 alleviated cardiac hypertrophy both in vivo and in vitro. Mechanically, TUG1 sponged and sequestered miR-34a to increase the Dickkopf 1 (DKK1) level, which eventually inhibited the activation of Wnt/β-catenin signalling. In conclusion, the current study reported the protective role and regulatory mechanism of TUG1 in cardiac hypertrophy and suggested that TUG1 may serve as a novel molecular target for treating cardiac hypertrophy.

Indexed as

Wnt Signaling PathwayAnimalsBase SequenceCardiomegalyGene Expression RegulationIntercellular Signaling Peptides and ProteinsMaleMice, Inbred C57BLMicroRNAsModels, BiologicalMyocytes, CardiacRNA, Long NoncodingDkk1 protein, mouseIntercellular Signaling Peptides and Proteinslong non-coding RNA TUG1, mouseMicroRNAsMIRN34a microRNA, mouseRNA, Long Noncodingcardiac hypertrophyDKK 1lncRNA TUG1miR-34aWnt/β-catenin signalling

Identifiers

PMID32057178
PMCPMC7131932
OpenAlexW3005848044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.